These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30646241)

  • 1. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Torres-Moreno MC; Papaseit E; Torrens M; Farré M
    JAMA Netw Open; 2018 Oct; 1(6):e183485. PubMed ID: 30646241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety].
    Mücke M; Carter C; Cuhls H; Prüß M; Radbruch L; Häuser W
    Schmerz; 2016 Feb; 30(1):25-36. PubMed ID: 26809975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
    Petzke F; Enax-Krumova EK; Häuser W
    Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
    Whiting PF; Wolff RF; Deshpande S; Di Nisio M; Duffy S; Hernandez AV; Keurentjes JC; Lang S; Misso K; Ryder S; Schmidlkofer S; Westwood M; Kleijnen J
    JAMA; 2015 Jun 23-30; 313(24):2456-73. PubMed ID: 26103030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Cannabinoids for Chronic Pain: Protocol for a Systematic Review.
    Mohiuddin MM; Mizubuti G; Haroutounian S; Smith S; Campbell F; Park R; Gilron I
    JMIR Res Protoc; 2019 Jan; 8(1):e11637. PubMed ID: 30688655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials.
    da Rovare VP; Magalhães GPA; Jardini GDA; Beraldo ML; Gameiro MO; Agarwal A; Luvizutto GJ; Paula-Ramos L; Camargo SEA; de Oliveira LD; Bazan R; El Dib R
    Complement Ther Med; 2017 Oct; 34():170-185. PubMed ID: 28917371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.
    Velayudhan L; McGoohan K; Bhattacharyya S
    PLoS Med; 2021 Mar; 18(3):e1003524. PubMed ID: 33780450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cannabinoids in multiple sclerosis. Opportunity or hazard?].
    Neuhaus O; Kieseier BC; Klimke A; Gaebel W; Hohlfeld R; Hartung HP
    Nervenarzt; 2004 Oct; 75(10):1022-6. PubMed ID: 15156287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis.
    Abo Youssef N; Schneider MP; Mordasini L; Ineichen BV; Bachmann LM; Chartier-Kastler E; Panicker JN; Kessler TM
    BJU Int; 2017 Apr; 119(4):515-521. PubMed ID: 28058780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
    Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.
    Pisani S; McGoohan K; Velayudhan L; Bhattacharyya S
    Drugs Aging; 2021 Oct; 38(10):887-910. PubMed ID: 34235645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of cannabinoids in palliative medicine.
    Mücke M; Weier M; Carter C; Copeland J; Degenhardt L; Cuhls H; Radbruch L; Häuser W; Conrad R
    J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):220-234. PubMed ID: 29400010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms.
    Allan GM; Finley CR; Ton J; Perry D; Ramji J; Crawford K; Lindblad AJ; Korownyk C; Kolber MR
    Can Fam Physician; 2018 Feb; 64(2):e78-e94. PubMed ID: 29449262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.